• Antimycin A4: ATP-Citrate Lyase Inhibitor Workflows

  2026-08-23

  Antimycin A4 connects ATP-citrate lyase inhibition with mitochondrial respiratory-chain analysis, enabling parallel studies of lipid biosynthesis and cellular energy failure. This practical guide outlines assay setup, dose-finding, orthogonal controls, and troubleshooting for reproducible metabolic experiments.

• NP-40 Lysis Buffer for Native Signaling

  2026-08-22

  NP-40 Lysis Buffer supports gentle extraction when phosphorylation states and protein complexes matter, from neuroimmune signaling to immunoprecipitation. This workflow-focused guide shows how to adapt one mild, non-denaturing chemistry across animal, plant, fungal, and bacterial samples while avoiding common losses in yield and interaction fidelity.

• Azithromycin: An Assay-Centered Research Framework

  2026-08-22

  Azithromycin is a macrolide antibiotic whose value in research depends on connecting ribosomal mechanism, resistance benchmarks, model selection, and analytical control. This guide presents an assay-centered framework for interpreting antimicrobial and trypanocidal data without overextending evidence across experimental domains.

• Ridaforolimus Workflows for mTOR Research

  2026-08-21

  Build mechanism-first cancer and senescence experiments around nanomolar mTOR inhibition, phospho-signaling validation, and phenotype-resolved controls. Ridaforolimus supports differentiated workflows spanning antiproliferative profiling, apoptosis assay design, VEGF-linked angiogenesis inhibition, and AI-guided senescence research.

• Alosetron Workflows for 5-HT3 Research

  2026-08-20

  Build receptor-focused assays around Alosetron to study serotonin-dependent gastrointestinal motility, visceral pain signaling, and epithelial responses. This workflow uses the CDC42–YAP–EGF–mTOR study as mechanistic context while clearly separating established findings from testable Alosetron hypotheses.

• (-)-Blebbistatin in Mechanomemory Assays

  2026-08-20

  Explore how (-)-Blebbistatin, a selective non-muscle myosin II inhibitor, can help separate actomyosin force transmission from YAP-dependent mechanomemory. This article translates recent intermittent-stress findings into practical assay design, controls, and interpretation strategies.

• Angiotensin I: Analytical Design for RAS Assays

  2026-08-19

  Angiotensin I is more than a precursor of angiotensin II: it is a controllable substrate for dissecting renin–ACE pathway behavior. This guide combines peptide mechanism, assay architecture, and a spectroscopy-derived framework for recognizing and managing analytical interference.

• Neomycin sulfate: RNA/DNA Assay Workflows

  2026-08-19

  Build better mechanistic assays with Neomycin sulfate, from hammerhead ribozyme turnover and HIV-1 TAR recognition to DNA triplex and ryanodine receptor studies. This workflow-focused guide also explains how to adapt antibiotic-perturbation logic from microbiome research without confusing exploratory use with validated therapeutic evidence.

• IGF2BP3–EPOR mRNA Stability in AML

  2026-08-18

  Fan et al. identify the m6A reader IGF2BP3 as a prognostic and functional driver of acute myeloid leukemia by promoting EPOR mRNA stability and JAK/STAT signaling. The study combines computational survival modeling with cellular perturbation, providing a framework for testing RNA stability, transcriptional stress, and leukemia-cell phenotypes.

• Separating Growth Inhibition from Cancer Cell Death

  2026-08-18

  Hannah Schwartz’s dissertation shows why in vitro anticancer drug responses should not be represented by a single viability metric. By distinguishing relative viability from fractional viability, the study clarifies how drugs combine proliferative arrest and cell killing, and why response timing is essential for interpretation.

• GI 254023X: A Translational Lens on ADAM10

  2026-08-17

  GI 254023X offers a selective way to interrogate ADAM10 sheddase biology across Notch1 signaling, Jurkat-cell phenotypes, and endothelial barrier injury. This thought-leadership perspective moves beyond potency claims to show how researchers can design more discriminating translational experiments while separating established evidence from forward-looking hypotheses.

• Lumiracoxib: A Causal Map for COX-2 Assays

  2026-08-17

  Lumiracoxib is a selective COX-2 inhibitor that can do more than suppress inflammatory prostaglandins: it can reveal when COX-2 signaling protects or restrains tissue repair. This article presents a causal assay framework for separating target engagement, mediator changes, and vascular phenotypes in inflammation research.

• Intermittent Stress, F-Actin, and YAP Mechanomemory

  2026-08-16

  The reference study shows that brief, repeated integrin-mediated stresses can produce stronger post-stress YAP nuclear translocation than a single stress episode of similar overall duration. Its central mechanistic insight is that intermittent loading increases cytoplasmic F-actin and engages actomyosin-dependent mechanotransduction, establishing a temporal form of cellular mechanomemory.

• Central Control of Opioid Mechanical Hypersensitivity

  2026-08-15

  The reference study identifies a lPBN-to-spinal circuit linking MOR-expressing neurons, hypothalamic dynorphin neurons, and KOR-expressing inhibitory neurons in the spinal dorsal horn as a regulator of morphine-induced mechanical hypersensitivity and tolerance. Its circuit-specific experiments distinguish mechanical from thermal opioid effects and suggest experimental strategies for dissecting opioid receptor signaling in pain models.

• Chloroquine BA1002: Practical Research Protocol

  2026-08-14

  This guide explains how to prepare, apply, and quality-check Chloroquine (BA1002) in lysosomal, autophagy, cancer, antiviral, malaria, and immune-modulation workflows. It is intended for controlled laboratory research, not for converting dossier or clinical information into patient dosing or assuming efficacy in an unvalidated model.

806 records 10/54 page Previous Next First page 上5页 678910 下5页 Last page